4//SEC Filing
Sullivan Ryan T 4
Accession 0001104659-19-064832
CIK 0001270073other
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 7:02 PM ET
Size
10.7 KB
Accession
0001104659-19-064832
Insider Transaction Report
Form 4
Sullivan Ryan T
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2019-11-13$53.41/sh+500$26,705→ 26,929 total - Sale
Common Stock
2019-11-13$85.00/sh−500$42,500→ 26,429 total - Tax Payment
Common Stock
2019-11-13$83.92/sh−711$59,667→ 25,718 total - Exercise/Conversion
Option to Purchase Common Stock
2019-11-13−500→ 34,800 totalExercise: $53.41Exp: 2028-02-13→ Common Stock (500 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.
- [F3]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 13, 2018.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001578823
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 7:02 PM ET
- Size
- 10.7 KB